Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMDA-MMC versus BCG adjuvant treatment in high-grade non-muscle-invasive bladder cancer
2018-004273-27Phase 4Active
- Sponsor
- Presurgy
- Start
- Jan 2019
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of mitomycin c and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) and bladder cancer (2 arms), sponsored by Presurgy. Primary endpoint: Disease-free survival. Started Jan 2019; status: active.
02
Drugs
mitomycin cbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)bladder cancer
Beyond the preview
Go deeper on 2018-004273-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004273-27.